MedDataX Logo

Long-term Consequences of Neuroimaging and Perceived Cognitive Dysfunction in oPRES

NCT ID: NCT05140850

Last Updated: 2021-12-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

500 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-01-31

Study Completion Date

2023-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to explore the long-term consequences of neuroimaging and perceived cognitive dysfunction in obstetrics posterior reversible encephalopathy syndrome.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective study. The investigators divided the PE or E patients into two groups, namely PRES group and non-PRES group, according to diagnostic criteria . The general information（demographic data，blood pressure.etc.）and blood sample will be collected. Additionally,all patients receive neuroimaging examination（DTI,ASL,3D-TMI.etc.）and neuro-cognitive test（MMSE,MOCA,CFQ, etc.） to assess the cerebral white matter lesions and cognitive changes.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroimaging Cognitive Dysfunction Posterior Reversible Encephalopathy Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PRES group

PE or E with PRES

neuroimaging examination,neuro-cognitive test,blood pressure,blood sample

Intervention Type BIOLOGICAL

neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested

non-PRES group

PE or E without PRES

neuroimaging examination,neuro-cognitive test,blood pressure,blood sample

Intervention Type BIOLOGICAL

neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

neuroimaging examination,neuro-cognitive test,blood pressure,blood sample

neuroimaging will be perform,neuro-cognitive will be tested,blood pressure will be monitored,blood samples will be tested

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients were diagnosed of PE or E
2. patients received cranial image examination
3. patients consent to participate

Exclusion Criteria

1. patients combined other neurological diseases
2. patients combined mental illness
Minimum Eligible Age

15 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Dunjin Chen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Dunjin Chen

Director of obstetrics

Responsibility Role SPONSOR_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Obstetrics and Gynecology, Key Laboratory for Major Obstetric Diseases of Guangdong Province, The Third Affiliated Hospital of Guangzhou Medical University

Guangzhou, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Dunjin Chen

Role: CONTACT

Phone: 18928916722

Email: [email protected]

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

82001568

Identifier Type: -

Identifier Source: org_study_id